Week in Review China Life Science Starts off 2019 with $425 Million in Deals

Week in Review: China Life Science Starts off 2019 with $425 Million in Deals

Deals and Financings 

Trials and Approvals 

• Aslan Pharma will begin a US Phase II trial of ASLAN003, an oral inhibitor of DHODH, in patients with acute myeloid leukemia; 
• Cellular Biomedicine, a Shanghai immunotherapy/stem cell company, started a China trial of its anti-BCMA CAR-T therapy for multiple myeloma;
• Biohaven Pharma of New Haven reported China's NMPA has accepted its IND filing for rimegepant as a treatment for migraine.

Stock symbols: (SHA: 603259; HK: 2359) (NSDQ: ASLN, TPEx: 6497) (NSDQ: UBX) (HK: 1530) (HK: 2269) (NSDQ: ASLN, TPEx: 6497) (NSDQ: CBMG) (NYSE: BHVN)

Share this with colleagues:

More From BioPortfolio on "Week in Review: China Life Science Starts off 2019 with $425 Million in Deals"